Semaglutide vs tirzepatide weight loss

A Booming GLP‑1 Market and the Role of Compounding

The GLP‑1 receptor agonist market is projected to surge from today’s levels to $157.5 billion by 2035, driven by rising demand for obesity and diabetes therapies. Independent compounding pharmacies carved out a niche during the 2022–2024 shortages of semaglutide and tirzepatide, offering patient‑specific preparations at lower cash‑pay prices. As the market expands, these small‑scale compounders face both opportunity and mounting regulatory scrutiny.

Evolving FDA Oversight & Implications for Compounders

Photo of Ozempic for weight loss

Since the Drug Quality and Security Act (DQSA) of 2013, compounding operations have been split under Section 503A (state‑licensed, patient‑specific) and 503B (outsourcing facilities, cGMP‑compliant). In early 2025, the FDA removed semaglutide and tirzepatide from its shortage list, thereby rescinding the § 506C shortage exception, and directed both 503A and 503B compounders to cease “essentially a copy” preparations within 60 days. Moving forward, the FDA is expected to:

  • Refine bulk‑API nomination processes for genuine scarcity events.

  • Update cGMP guidelines for biologic compounding, closing gaps exposed by prior outbreaks.

  • Increase collaboration with state boards via its Inter‑governmental Working Meeting on Drug Compounding series, most recently convened November 2023.

These shifts underscore a future where compounded weight‑loss injectables must meet even tighter safety, documentation, and manufacturing criteria.

Rise of Biosimilars & Alternative Supply Channels 

With branded GLP‑1 manufacturers scaling up, biosimilars and generic peptides are next on the horizon:

  • Financial analysts forecast the GLP‑1 class will exceed $100 billion in annual sales by 2030, incentivizing swift biosimilar filings.

  • The FDA has signaled its readiness to evaluate follow‑on biologics under the 351(k) pathway, potentially approving the first semaglutide and tirzepatide biosimilars as early as 2026.

These developments will expand patient access to FDA‑regulated, cost‑effective weight‑loss treatments outside traditional compounding channels. 

Emerging Technologies & Personalized Medicine

Client getting injected with a GLP-1.

Looking ahead, compounding pharmacies may adopt novel approaches to remain viable:

  • 3D‑printed dosage forms for ultra‑precise peptide layering, currently under investigation in academic labs.

  • On‑site automated compounding robots integrating real‑time sterility and potency testing, FDA pilot programs for such devices may begin by 2026.

  • Pharmacogenomic‑guided formulations, customizing GLP‑1 analog doses based on individual metabolic gene profiles (e.g., GLP1R variants), a frontier explored in Nature Medicine.

As regulatory frameworks evolve, these advanced compounding methods will need to align with updated USP standards and FDA guidances to ensure safety and efficacy.

Preparing for Tomorrow at New Results Medical Weight Loss

At New Results Medical Weight Loss (Mesa & Scottsdale), we’re staying ahead of emerging trends to deliver safe, effective care:

  1. Monitoring Biosimilar Approvals - Securing low‑cost, FDA‑approved generics as soon as they’re cleared.

  2. Partnering with Accredited Outsourcing Facilities - Ensuring any necessary compounded supplies meet the latest cGMP expectations.

  3. Integrating Personalized Medicine - Leveraging pharmacogenomic insights and digital health tools for truly tailored dosing.

  4. Ongoing Regulatory Insight - Our team attends FDA/state compounding workshops to anticipate policy changes and protect your access.

📞 Call  or book online today to discuss how we’ll navigate the shifting landscape of weight‑loss therapies,keeping you on track with cutting‑edge, compliant options that fit your goals.